Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program
April 29 2024 - 5:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, announced that Sendai Tokushukai Hospital in Japan has
entered into an agreement to lease and utilize a Senhance® Surgical
System.
"We're happy that Sendai Tokushukai Hospital has
initiated a lease on the Senhance System, becoming the second
institution within one of Japan's largest private hospital systems
to do so," said Anthony Fernando, President and CEO of Asensus
Surgical. "This underscores the growing trust in Asensus Surgical's
technology in Japan, and we're excited to collaborate with Sendai
Tokushukai Hospital to enhance surgical standards."
“On behalf of Sendai Tokushukai Hospital we are
pleased to lease a Senhance System in our facility,” said Kei
Kawaguchi, Chief of Surgery. “The Senhance System offers innovative
features such as haptic feedback, enhancing our surgical
capabilities and facilitating precise procedures. Through this
collaboration, we aim to elevate patient care and outcomes,
aligning with our commitment to excellence.
The Senhance Surgical System is the only
commercially available robotic surgery system with haptic feedback,
a differentiating feature for surgeons.
About Sendai Tokushukai
Hospital
Established on February 1, 1985, Sendai
Tokushukai Hospital is a respected general and acute care facility.
Under the leadership of Shinichi Higashiue and administratively
managed by Hisayoshi Inoue, the hospital serves as an essential
healthcare provider in the region and offers a diverse range of
medical services, including Internal Medicine, Gastroenterology,
Surgery, Orthopedics, and others. The Tokushukai Medical Group
Facility oversees 71 hospitals across Japan and their philosophy is
“All living beings are created equal”. Under this philosophy, they
continuously strive for realizing “Anybody in the society is to
receive the best possible medical care anywhere, whenever
necessary”. From Emergency Medical Care to preventive health care,
chronic care and advanced care, we provide the optimal medical
care.
About Asensus Surgical, Inc.
Asensus Surgical is revolutionizing surgery with
the first intra-operative Augmented Intelligence technology
approved for use in operating rooms around the world. Recognized as
an award-winning leader in digital technology, Asensus is committed
to making surgery more accessible and predictable while delivering
consistently superior outcomes. The Company’s novel approach to
digitizing laparoscopy has led to system placements globally. Led
by engineers, medical professionals, and industry luminaries,
Asensus is powered by human ingenuity and driven by collaboration.
To learn more about the Senhance® Surgical System and the new LUNA™
System in development, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc/
X: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
TikTok:https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating
to the Senhance Surgical System and Sendai Tokushukai Hospital in
Japan initiating a program with the Senhance System. These
statements and other statements regarding our future plans and
goals constitute "forward looking statements'' within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether Asensus
Surgical can accelerate the adoption of the Senhance Surgical
System throughout Japan and other key geographies around the world
and whether the Senhance Surgical System will enable Sendai
Tokushukai Hospital to elevate its patient care and outcomes. For a
discussion of the risks and uncertainties associated with the
Company’s business, please review our filings with the Securities
and Exchange Commission (SEC), including our Annual Report on Form
10-K for the year ended December 31, 2023, filed with the SEC on
March 21, 2024 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike VallieICR
Westwickeinvest@asensus.com443-213-0499
MEDIA CONTACT:Dan VentrescaMatter
CommunicationsAsensusPR@matternow.com617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0ba0a44c-320c-4698-b7f1-5149c823ad60
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2024 to May 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From May 2023 to May 2024